DCPS program

Sprint Bioscience is developing a first-in-class small molecule inhibitor program targeting the Decapping Scavenger enzyme (DCPS) for the treatment of acute myeloid leukemia (AML). DCPS is an enzyme that plays a central role in cellular RNA processing and pre-mRNA metabolic pathways. Preclinical development has shown that both small molecule inhibition and genetic inactivation of DCPS impair the differentiation and proliferation of several AML cell lines and patient-derived samples, while healthy tissues remain largely unaffected. Sprint Bioscience has identified potential predictive biomarkers for patient selection, including low levels of the FHIT protein and the presence of IDH2 mutations, which correlate with increased sensitivity to DCPS inhibition.

Other names

DCPS inhibitorDecapping Scavenger enzyme inhibitor